AbbVie is one step closer to challenging Gilead Sciences’ dominance in the hepatitis C market, securing a likely European approval for its rival combo treatment as it awaits a U.S. nod.

…read more

Source: AbbVie gets an EU green light for its next-gen hep C treatment


0 No comments